Komori
Share Issuance and Disposal190AChordia Therapeutics Inc.Pharmaceuticals

Notice Concerning a Reduction in the Amount of Capital Reserve and Disposition of Surplus

The Company resolved to transfer ¥1,455,144,346 from capital reserve to other capital surplus, and then to retained earnings brought forward to offset the deficit. Net assets and the total number of shares issued will remain unchanged.

Worth reading
24Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1455144346
¥
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Type of issuance/disposition

発行済株式総数

No change

Not applicable (no change in the total number of shares issued)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Impact on Business Performance
As net assets and the total number of shares issued will remain unchanged, there will be no change in net assets per share.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalType of issuance/disposition
Dilution RateNot applicable (no change in the total number of shares issued)
Total number of issued sharesNo change
Impact on Business PerformanceAs net assets and the total number of shares issued will remain unchanged, there will be no change in net assets per share.
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To offset the deficit currently incurred, ensure flexibility and agility in future capital policy, and optimize the capital structure.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning a Reduction in the Amount of Capital Reserve and Disposition of Surplus | Chordia Therapeutics Inc. (190A) timely disclosure | Komori